Loading...
•
Mar 31, 2024
Zimmer Biomet Q1 2024 Earnings Report
Reported an increase in net sales and adjusted diluted earnings per share in the first quarter of 2024 and reiterated full-year 2024 financial guidance.
Key Takeaways
Zimmer Biomet reported first quarter net sales of $1.889 billion, a 3.2% increase over the prior year, and a 4.4% increase on a constant currency basis. Diluted earnings per share were $0.84, and adjusted diluted earnings per share were $1.94. The company reiterated its full-year 2024 financial guidance.
First quarter net sales of $1.889 billion increased 3.2% and 4.4% on a constant currency basis.
First quarter diluted earnings per share were $0.84; adjusted diluted earnings per share were $1.94.
Company reiterates full-year 2024 financial guidance
Received FDA 510(k) clearance for the ROSA® Shoulder System and the Z1 Femoral Hip Stem.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The Company is reiterating its current full-year 2024 financial guidance.
Positive Outlook
- 2024 Reported Revenue Change 4.5% - 5.5%
- 2024 Constant Currency Revenue Change 5.0% - 6.0%
- Adjusted Diluted EPS $8.00 - $8.15
Challenges Ahead
- Foreign Currency Exchange Impact (0.5)%
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...